Pharmacological Treatment of Alcohol use Disorder in Patients with
Psychotic Disorders: A Systematic Review

Niels   Jørgen   Rosenstand; Anette   Søgaard   Nielsen; Lotte      Skøt; Simon      Anhøj; Dorthe   Grüner   Nielsen; Mikkel      Højlund; Angelina   Isabella   Mellentin

Abstract

Background: Patients with psychotic disorders (PD) often have comorbid alcohol use disorder (AUD), which is typically treated pharmacologically. Up till now, no systematic review has examined the effectiveness and safety of AUD treatment in PD patients.

Objectives: This study aimed to systematically review the literature on (1) the effects of pharmacological treatments for AUD on drinking outcomes, (2) the side effects of the drugs, and (3) the effects of polypharmacy in patients with comorbid AUD and PD.

Methods: Bibliographic searches were conducted in MEDLINE, Embase, Cochrane Central Register of Controlled Trials, and PsycINFO. At least two reviewers extracted the data, assessed the risk of bias, and performed the qualitative synthesis of the collected evidence.

Results: Twelve eligible studies were identified, half being randomized controlled trials (RCTs). Three studies examined disulfiram, nine naltrexone, two acamprosate, and one nalmefene by comparing the effects of treatment to placebo, baseline, or pharmacological agents. Disulfiram and naltrexone were shown to reduce alcohol intake. Regarding acamprosate, the findings were mixed. Nalmefene decreased alcohol intake. All pharmacological agents appeared safe to use as AUD monotherapy, but cardiac events were reported when combining naltrexone and disulfiram. Nine studies had a high risk of bias, and three had some other concerns.

Conclusion: The studies provide tentative support for the use of naltrexone and disulfiram in this population, although combinations of pharmacological AUD treatments and other polypharmacy remain unexplored. The studies had high adherence rates that are hardly replicable in real-world settings. Thus, the findings should be confirmed in larger high quality efficacy and effectiveness RCTs with longer follow-ups.

[1]
Mueser, K.T.; Yarnold, P.R.; Levinson, D.F.; Singh, H.; Bellack, A.S.; Kee, K.; Morisson, R.L.; Yadalam, K.G. Prevalence of substance abuse in schizophrenia: Demographic and clinical correlates. Schizophr. Bull.,  1990, 16(1), 31-56.
 [http://dx.doi.org/10.1093/schbul/16.1.31] [PMID:  2333480]

[2]
Archibald, L.; Brunette, M.F.; Wallin, D.J.; Green, A.I. Alcohol use disorder and schizophrenia and schizoaffective disorders. Alcohol Res.,  2019, 40(1)
 [http://dx.doi.org/10.1186/2045-8118-11-26] [PMID: 25678956]

[3]
Regier, D.A.; Farmer, M.E.; Rae, D.S.; Locke, B.Z.; Keith, S.J.; Judd, L.L.; Goodwin, F.K. Comorbidity of mental disorders with alcohol and other drug abuse. Results from the Epidemiologic Catchment Area (ECA) Study. JAMA,  1990, 264(19), 2511-2518.
 [http://dx.doi.org/10.1001/jama.1990.03450190043026] [PMID:  2232018]

[4]
Koskinen, J.; Löhönen, J.; Koponen, H.; Isohanni, M.; Miettunen, J. Prevalence of alcohol use disorders in schizophrenia - a systematic review and meta-analysis. Acta Psychiatr. Scand.,  2009, 120(2), 85-96.
 [http://dx.doi.org/10.1111/j.1600-0447.2009.01385.x] [PMID:  19374633]

[5]
Gerding, L.B.; Labbate, L.A.; Measom, M.O.; Santos, A.B.; Arana, G.W. Alcohol dependence and hospitalization in schizophrenia. Schizophr. Res.,  1999, 38(1), 71-75.
 [http://dx.doi.org/10.1016/S0920-9964(98)00177-7] [PMID:  10427612]

[6]
Lorine, K.; Goenjian, H.; Kim, S.; Steinberg, A.M.; Schmidt, K.; Goenjian, A.K. Risk factors associated with psychiatric readmission. J. Nerv. Ment. Dis.,  2015, 203(6), 425-430.
 [http://dx.doi.org/10.1097/NMD.0000000000000305] [PMID:  25974053]

[7]
Dixon, L. Dual diagnosis of substance abuse in schizophrenia: Prevalence and impact on outcomes. Schizophr. Res.,  1999, 35(Suppl.), S93-S100.
 [http://dx.doi.org/10.1016/S0920-9964(98)00161-3] [PMID:  10190230]

[8]
Owen, R.R.; Fischer, E.P.; Booth, B.M.; Cuffel, B.J. Medication noncompliance and substance abuse among patients with schizophrenia. Psychiatr. Serv.,  1996, 47(8), 853-858.
 [http://dx.doi.org/10.1176/ps.47.8.853] [PMID:  8837158]

[9]
Sundhedsstyrelsen. NKR: Behandling af alkoholafhængighed. 2018. Available on:
          https://www.sst.dk/da/udgivelser/2018/nkr-behandling-af-alkoholafhaengighed

[10]
National Institute for Health and Care Excellence. Alcohol-use disorders: Diagnosis, assessment and management of harmful drinking (high-risk drinking) and alcohol dependence; , 2011.  Available on: [https://www.nice.org.uk/guidance/cg115]

[11]
Food and Drug Administration. Drugs@FDA: FDA-approved drugs; , 2022.  Available on: [https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm]

[12]
European Medicines Agency. Medicines. 2022. Available on:
          https://www.ema.europa.eu/en/human-regulatory/post-authorisation/data-medicines-iso-idmp-standards/public-data-article-57-database

[13]
European Medicines Agency. Development of medicinal products for the treatment of alcohol dependence; , 2010.  Available on: [https://www.ema.europa.eu/en/development-medicinal-products-treatment-alcohol-dependence]

[14]
National Collaborating Centre for Mental Health (UK). Alcohol-Use Disorders: Diagnosis, Assessment and Management of Harmful Drinking and Alcohol Dependence; British Psychological Society: Leicester, UK, 2011. 

[15]
Skinner, M.D.; Lahmek, P.; Pham, H.; Aubin, H.J. Disulfiram efficacy in the treatment of alcohol dependence: A meta-analysis. PLoS One,  2014, 9(2), e87366.
 [http://dx.doi.org/10.1371/journal.pone.0087366] [PMID:  24520330]

[16]
Donoghue, K.; Elzerbi, C.; Saunders, R.; Whittington, C.; Pilling, S.; Drummond, C. The efficacy of acamprosate and naltrexone in the treatment of alcohol dependence, Europe versus the rest of the world: A meta-analysis. Addiction,  2015, 110(6), 920-930.
 [http://dx.doi.org/10.1111/add.12875] [PMID:  25664494]

[17]
Mann, K.; Torup, L.; Sørensen, P.; Gual, A.; Swift, R.; Walker, B.; van den Brink, W. Nalmefene for the management of alcohol dependence: Review on its pharmacology, mechanism of action and meta-analysis on its clinical efficacy. Eur. Neuropsychopharmacol.,  2016, 26(12), 1941-1949.
 [http://dx.doi.org/10.1016/j.euroneuro.2016.10.008] [PMID:  27842940]

[18]
Fuller, R.K.; Branchey, L.; Brightwell, D.R.; Derman, R.M.; Emrick, C.D.; Iber, F.L.; James, K.E.; Lacoursiere, R.B.; Lee, K.K.; Lowenstam, I. Disulfiram treatment of alcoholism. A Veterans Administration cooperative study. JAMA,  1986, 256(11), 1449-1455.
 [http://dx.doi.org/10.1001/jama.1986.03380110055026] [PMID:  3528541]

[19]
Mueser, K.T.; Noordsy, D.L.; Fox, L.; Wolfe, R. Disulfiram treatment for alcoholism in severe mental illness. Am. J. Addict.,  2003, 12(3), 242-252.
 [http://dx.doi.org/10.1111/j.1521-0391.2003.tb00652.x] [PMID:  12851020]

[20]
Nasrallah, H.A. Vulnerability to disulfiram psychosis. West. J. Med.,  1979, 130(6), 575-577.
 [PMID:  516699]

[21]
Kalk, N.J.; Lingford-Hughes, A.R. The clinical pharmacology of acamprosate. Br. J. Clin. Pharmacol.,  2014, 77(2), 315-323.
 [http://dx.doi.org/10.1111/bcp.12070] [PMID:  23278595]

[22]
King, A.C.; Volpicelli, J.R.; Frazer, A.; O’Brien, C.P. Effect of naltrexone on subjective alcohol response in subjects at high and low risk for future alcohol dependence. Psychopharmacology (Berl.),  1997, 129(1), 15-22.
 [http://dx.doi.org/10.1007/s002130050156] [PMID:  9122358]

[23]
Bart, G.; Schluger, J.H.; Borg, L.; Ho, A.; Bidlack, J.M.; Kreek, M.J. Nalmefene induced elevation in serum prolactin in normal human volunteers: Partial kappa opioid agonist activity? Neuropsychopharmacology,  2005, 30(12), 2254-2262.
 [http://dx.doi.org/10.1038/sj.npp.1300811] [PMID:  15988468]

[24]
Barnas, C.; Hummer, M.; Fleischhacker, W.W. Compliance problems in treatment of schizophrenic patients. Wien. Med. Wochenschr.,  1998, 148(11-12), 281-283.
 [PMID:  9746971]

[25]
National Institute for Health and Care Excellence. Coexisting severe mental illness and substance misuse: Community health and health and social care services; , 2016.  Available on: [https://www.nice.org.uk/guidance/ng58]

[26]
National Institute for Health and Care Excellence. Coexisting severe mental illness (psychosis) and substance misuse: Assessment and management in healthcare settings; , 2011.  Available on: [https://www.nice.org.uk/guidance/cg120

[27]

Sundhedsstyrelsen. NKR: Udredning og behandling af personer med samtidig alkoholafhængighed og psykisk lidelse., 2019. Available on:
          https://www.sst.dk/da/udgivelser/2016/nkr-for-udredning-og-behandling-af-samtidig-alkoholafhaengighed-og-psykisk-lidelse

[28]
Bellack, A.S.; Gearon, J.S. Substance abuse treatment for people with schizophrenia. Addict. Behav.,  1998, 23(6), 749-766.
 [http://dx.doi.org/10.1016/S0306-4603(98)00066-5] [PMID:  9801714]

[29]
Bortolato, B.; Miskowiak, K.W.; Köhler, C.A.; Vieta, E.; Carvalho, A.F. Cognitive dysfunction in bipolar disorder and schizophrenia: A systematic review of meta-analyses. Neuropsychiatr. Dis. Treat.,  2015, 11, 3111-3125.
 [PMID:  26719696]

[30]
Sheffield, J.M.; Barch, D.M. Cognition and resting-state functional connectivity in schizophrenia. Neurosci. Biobehav. Rev.,  2016, 61, 108-120.
 [http://dx.doi.org/10.1016/j.neubiorev.2015.12.007] [PMID:  26698018]

[31]
Marder, S.R.; Cannon, T.D. Schizophrenia. N. Engl. J. Med.,  2019, 381(18), 1753-1761.
 [http://dx.doi.org/10.1056/NEJMra1808803] [PMID:  31665579]

[32]
Huhn, M.; Tardy, M.; Spineli, L.M.; Kissling, W.; Förstl, H.; Pitschel-Walz, G.; Leucht, C.; Samara, M.; Dold, M.; Davis, J.M.; Leucht, S. Efficacy of pharmacotherapy and psychotherapy for adult psychiatric disorders: A systematic overview of meta-analyses. JAMA Psychiatry,  2014, 71(6), 706-715.
 [http://dx.doi.org/10.1001/jamapsychiatry.2014.112] [PMID:  24789675]

[33]
Petrakis, I.L.; Leslie, D.; Rosenheck, R. Use of naltrexone in the treatment of alcoholism nationally in the Department of Veterans Affairs. Alcohol. Clin. Exp. Res.,  2003, 27(11), 1780-1784.
 [http://dx.doi.org/10.1097/01.ALC.0000095861.43232.19] [PMID:  14634494]

[34]
Iheanacho, T.; Issa, M.; Marienfeld, C.; Rosenheck, R. Use of naltrexone for alcohol use disorders in the Veterans’ Health Administration: A national study. Drug Alcohol Depend.,  2013, 132(1-2), 122-126.
 [http://dx.doi.org/10.1016/j.drugalcdep.2013.01.016] [PMID:  23434041]

[35]
Barnes, T.R.E.; Paton, C. Antipsychotic polypharmacy in schizophrenia: Benefits and risks. CNS Drugs,  2011, 25(5), 383-399.
 [http://dx.doi.org/10.2165/11587810-000000000-00000] [PMID:  21476610]

[36]
Baandrup, L. Polypharmacy in schizophrenia. Basic Clin. Pharmacol. Toxicol.,  2020, 126(3), 183-192.
 [http://dx.doi.org/10.1111/bcpt.13384] [PMID:  31908124]

[37]
Lin, S.K. Antipsychotic Polypharmacy: A Dirty Little Secret or a Fashion? Int. J. Neuropsychopharmacol.,  2020, 23(2), 125-131.
 [http://dx.doi.org/10.1093/ijnp/pyz068] [PMID:  31867671]

[38]
Higgins, J.P.T.; Thomas, J.; Chandler, J.; Cumpston, M.; Li, T.; Page, M.J.; Welch, V.A. Cochrane handbook for systematic reviews of interventions version 6.2 (updated February 2021). Cochrane., 2021. Available on: 
          www.training.cochrane.org/handbook

[39]
Moher, D.; Liberati, A.; Tetzlaff, J.; Altman, D.G. Preferred reporting items for systematic reviews and meta-analyses: The PRISMA statement. PLoS Med.,  2009, 6(7), e1000097.
 [http://dx.doi.org/10.1371/journal.pmed.1000097] [PMID:  19621072]

[40]
Sterne, J.A.C.; Savović, J.; Page, M.J.; Elbers, R.G.; Blencowe, N.S.; Boutron, I.; Cates, C.J.; Cheng, H.Y.; Corbett, M.S.; Eldridge, S.M.; Emberson, J.R.; Hernán, M.A.; Hopewell, S.; Hróbjartsson, A.; Junqueira, D.R.; Jüni, P.; Kirkham, J.J.; Lasserson, T.; Li, T.; McAleenan, A.; Reeves, B.C.; Shepperd, S.; Shrier, I.; Stewart, L.A.; Tilling, K.; White, I.R.; Whiting, P.F.; Higgins, J.P.T. RoB 2: A revised tool for assessing risk of bias in randomised trials. BMJ,  2019, 366, l4898.
 [http://dx.doi.org/10.1136/bmj.l4898] [PMID:  31462531]

[41]
Sterne, J.A.C.; Hernán, M.A.; Reeves, B.C.; Savović, J.; Berkman, N.D.; Viswanathan, M.; Henry, D.; Altman, D.G.; Ansari, M.T.; Boutron, I.; Carpenter, J.R.; Chan, A.W.; Churchill, R.; Deeks, J.J.; Hróbjartsson, A.; Kirkham, J.; Jüni, P.; Loke, Y.K.; Pigott, T.D.; Ramsay, C.R.; Regidor, D.; Rothstein, H.R.; Sandhu, L.; Santaguida, P.L.; Schünemann, H.J.; Shea, B.; Shrier, I.; Tugwell, P.; Turner, L.; Valentine, J.C.; Waddington, H.; Waters, E.; Wells, G.A.; Whiting, P.F.; Higgins, J.P.T. ROBINS-I: A tool for assessing risk of bias in non-randomised studies of interventions. BMJ,  2016, 355, i4919.
 [http://dx.doi.org/10.1136/bmj.i4919] [PMID:  27733354]

[42]
Petrakis, I.L.; Poling, J.; Levinson, C.; Nich, C.; Carroll, K.; Rounsaville, B. Naltrexone and disulfiram in patients with alcohol dependence and comorbid psychiatric disorders. Biol. Psychiatry,  2005, 57(10), 1128-1137.
 [http://dx.doi.org/10.1016/j.biopsych.2005.02.016] [PMID:  15866552]

[43]
Vasile, D.; Vasiliu, O.; Mangalagiu, A.G.; Petrescu, B.M.; Sopterean, G.A.; Bratu, R.E.P. 3.b.001 Pharmacological management of alcohol dependence in chronic schizophrenia. Eur. Neuropsychopharmacol.,  2013, 23, S429.
 [http://dx.doi.org/10.1016/S0924-977X(13)70679-5]

[44]
Petrakis, I.L.; O’Malley, S.; Rounsaville, B.; Poling, J.; McHugh-Strong, C.; Krystal, J.H. Naltrexone augmentation of neuroleptic treatment in alcohol abusing patients with schizophrenia. Psychopharmacology (Berl.),  2004, 172(3), 291-297.
 [http://dx.doi.org/10.1007/s00213-003-1658-9] [PMID:  14634716]

[45]
Batki, S.; Dimmock, J.; Ploutz-Snyder, R.; Meszaros, Z.; Canfield, K. Directly monitored naltrexone reduces heavy drinking in svhizophrenia: Preliminary analysis of a controlled trial: 411. Alcohol. Clin. Exp. Res.,  2009, 33.

[46]
Bratu, E.R.; Sopterean, G.A.P. 3.020 Comparison of the efficacies of naltrexone and acamprosate in the treatment of patients with chronic schizophrenia who are alcohol dependent. Eur. Neuropsychopharmacol.,  2014, 24, S71-S72.
 [http://dx.doi.org/10.1016/S0924-977X(14)70080-X]

[47]
Ralevski, E.; O’Brien, E.; Jane, J.S.; Dwan, R.; Dean, E.; Edens, E.; Arnaout, B.; Keegan, K.; Drew, S.; Petrakis, I. Treatment with acamprosate in patients with schizophrenia spectrum disorders and comorbid alcohol dependence. J. Dual Diagn.,  2011, 7(1-2), 64-73.
 [http://dx.doi.org/10.1080/15504263.2011.569440] [PMID:  26954912]

[48]
Batki, S.; Dimmock, J.; Meszaros, Z. Extended-release naltrexone for alcohol dependence in patients with serious mental illness: 661. Alcohol. Clin. Exp. Res.,  2010, 34(6)

[49]
Batki, S.L.; Dimmock, J.A.; Wade, M.; Gately, P.W.; Cornell, M.; Maisto, S.A.; Carey, K.B.; Ploutz-Snyder, R. Monitored naltrexone without counseling for alcohol abuse/dependence in schizophrenia-spectrum disorders. Am. J. Addict.,  2007, 16(4), 253-259.
 [http://dx.doi.org/10.1080/10550490701389732] [PMID:  17661192]

[50]
Vasile, D.; Vasiliu, O.; Sopterean, G.A.; Bratu, R.E.; Androne, F.; Vasile, F.P. 3.d.028 Effectiveness and tolerability of nalmefene in alcohol use dependence comorbid with schizophrenia. Eur. Neuropsychopharmacol.,  2014, 24, S538.
 [http://dx.doi.org/10.1016/S0924-977X(14)70861-2]

[51]
Maxwell, S.; Shinderman, M.S. Use of naltrexone in the treatment of alcohol use disorders in patients with concomitant major mental illness. J. Addict. Dis.,  2000, 19(3), 61-69.
 [http://dx.doi.org/10.1300/J069v19n03_05] [PMID:  11076120]

[52]
Vasiliu, O.P. 796 Therapeutic management of young patients with schizoaffective disorder and alcohol use disorder dual diagnosis. Eur. Neuropsychopharmacol.,  2020, 40, S450.
 [http://dx.doi.org/10.1016/j.euroneuro.2020.09.585]

[53]
Petrakis, I.L.; Nich, C.; Ralevski, E. Psychotic spectrum disorders and alcohol abuse: A review of pharmacotherapeutic strategies and a report on the effectiveness of naltrexone and disulfiram. Schizophr. Bull.,  2005, 32(4), 644-654.
 [http://dx.doi.org/10.1093/schbul/sbl010] [PMID:  16887890]

[54]
Grüner Nielsen, D.; Andersen, K.; Søgaard Nielsen, A.; Juhl, C.; Mellentin, A. Consistency between self-reported alcohol consumption and biological markers among patients with alcohol use disorder – A systematic review. Neurosci. Biobehav. Rev.,  2021, 124, 370-385.
 [http://dx.doi.org/10.1016/j.neubiorev.2021.02.006] [PMID:  33581224]

[55]
Das, N.; Mahapatra, A.; Sarkar, S. Disulfiram induced psychosis: Revisiting an age-old entity. Asian J. Psychiatr.,  2017, 30, 94-95.
 [http://dx.doi.org/10.1016/j.ajp.2017.08.011] [PMID:  28843144]

[56]
Fuller, R.; Roth, H.; Long, S. Compliance with disulfiram treatment of alcoholism. J. Chronic Dis.,  1983, 36(2), 161-170.
 [http://dx.doi.org/10.1016/0021-9681(83)90090-5] [PMID:  6337171]

[57]
O’Farrell, T.J.; Bayog, R.D. Antabuse contracts for married alcoholics and their spouses: A method to maintain antabuse ingestion and decrease conflict about drinking. J. Subst. Abuse Treat.,  1986, 3(1), 1-8.
 [http://dx.doi.org/10.1016/0740-5472(86)90002-4] [PMID:  3735473]

[58]
Krampe, H.; Ehrenreich, H. Supervised disulfiram as adjunct to psychotherapy in alcoholism treatment. Curr. Pharm. Des.,  2010, 16(19), 2076-2090.
 [http://dx.doi.org/10.2174/138161210791516431] [PMID:  20482514]

[59]
Salles, J.; Ponté, C.; Schmitt, L. Psychotic decompensation during nalmefene treatment in a patient with schizoaffective disorder: A case report. J. Dual Diagn.,  2019, 15(2), 118-121.
 [http://dx.doi.org/10.1080/15504263.2019.1574367] [PMID:  30829564]

[60]
Zhornitsky, S.; Rizkallah, É.; Pampoulova, T.; Chiasson, J.P.; Stip, E.; Rompré, P.P.; Potvin, S. Antipsychotic agents for the treatment of substance use disorders in patients with and without comorbid psychosis. J. Clin. Psychopharmacol.,  2010, 30(4), 417-424.
 [http://dx.doi.org/10.1097/JCP.0b013e3181e7810a] [PMID:  20631559]

[61]
Morris, P.L.P.; Hopwood, M.; Whelan, G.; Gardiner, J.; Drummond, E. Naltrexone for alcohol dependence: A randomized controlled trial. Addiction,  2001, 96(11), 1565-1573.
 [http://dx.doi.org/10.1046/j.1360-0443.2001.961115654.x] [PMID:  11784454]

[62]
Volpicelli, J.R.; Rhines, K.C.; Rhines, J.S.; Volpicelli, L.A.; Alterman, A.I.; O’Brien, C.P. Naltrexone and alcohol dependence. Role of subject compliance. Arch. Gen. Psychiatry,  1997, 54(8), 737-742.
 [http://dx.doi.org/10.1001/archpsyc.1997.01830200071010] [PMID:  9283509]

[63]
Mason, B.J.; Lehert, P. Acamprosate for alcohol dependence: A sex-specific meta-analysis based on individual patient data. Alcohol. Clin. Exp. Res.,  2012, 36(3), 497-508.
 [http://dx.doi.org/10.1111/j.1530-0277.2011.01616.x] [PMID:  21895717]

[64]
Greenfield, S.F.; Pettinati, H.M.; O’Malley, S.; Randall, P.K.; Randall, C.L. Gender differences in alcohol treatment: An analysis of outcome from the COMBINE study. Alcohol. Clin. Exp. Res.,  2010, 34(10), 1803-1812.
 [http://dx.doi.org/10.1111/j.1530-0277.2010.01267.x] [PMID:  20645934]

[65]
Jackson, J.J.; Thoemmes, F.; Jonkmann, K.; Lüdtke, O.; Trautwein, U. Military training and personality trait development: Does the military make the man, or does the man make the military? Psychol. Sci.,  2012, 23(3), 270-277.
 [http://dx.doi.org/10.1177/0956797611423545] [PMID:  22275337]

[66]
Spence, N.J.; Henderson, K.A.; Elder, G.H., Jr Does adolescent family structure predict military enlistment? A comparison of post–high school activities. J. Fam. Issues,  2013, 34(9), 1194-1216.
 [http://dx.doi.org/10.1177/0192513X12457347] [PMID:  24000268]

[67]
Mankowski, M.; Tower, L.E.; Brandt, C.A.; Mattocks, K. Why women join the military: Enlistment decisions and postdeployment experiences of service members and veterans. Soc. Work,  2015, 60(4), 315-323.
 [http://dx.doi.org/10.1093/sw/swv035] [PMID:  26489352]

[68]
Xue, C.; Ge, Y.; Tang, B.; Liu, Y.; Kang, P.; Wang, M.; Zhang, L. A meta-analysis of risk factors for combat-related PTSD among military personnel and veterans. PLoS One,  2015, 10(3), e0120270.
 [http://dx.doi.org/10.1371/journal.pone.0120270] [PMID:  25793582]

[69]
Ray, L.A.; Oslin, D.W. Naltrexone for the treatment of alcohol dependence among African Americans: Results from the COMBINE Study. Drug Alcohol Depend.,  2009, 105(3), 256-258.
 [http://dx.doi.org/10.1016/j.drugalcdep.2009.07.006] [PMID:  19717248]

[70]
Plebani, J.G.; Oslin, D.W.; Lynch, K.G. Examining naltrexone and alcohol effects in a minority population: Results from an initial human laboratory study. Am. J. Addict.,  2011, 20(4), 330-336.
 [http://dx.doi.org/10.1111/j.1521-0391.2011.00138.x] [PMID:  21679264]

[71]
Sanchez-Roige, S.; Palmer, A.A.; Clarke, T.K. Recent efforts to dissect the genetic basis of alcohol use and abuse. Biol. Psychiatry,  2020, 87(7), 609-618.
 [http://dx.doi.org/10.1016/j.biopsych.2019.09.011] [PMID:  31733789]

[72]
Castaldelli-Maia, J.M.; Malbergier, A.; de Oliveira, A.B.P.; Amaral, R.A.; Negrão, A.B.; Gonçalves, P.D.; Ventriglio, A.; de Berardis, D.; de Antonio, J.; Firigato, I.; Gattás, G.J.F.; de Toledo Gonçalves, F. Exploring the role of alcohol metabolizing genotypes in a 12-week clinical trial of naltrexone for alcohol use disorder. Biomolecules,  2021, 11(10), 1495.
 [http://dx.doi.org/10.3390/biom11101495] [PMID:  34680127]

[73]
Tek, C.; Srihari, V.; Tek, E. Successful acamprosate treatment of alcohol dependence in schizophrenia. Schizophr. Res.,  2008, 106(2-3), 373.
 [http://dx.doi.org/10.1016/j.schres.2008.08.010] [PMID:  18804961]

[74]
Krystal, J.H.; Cramer, J.A.; Krol, W.F.; Kirk, G.F.; Rosenheck, R.A. Naltrexone in the treatment of alcohol dependence. N. Engl. J. Med.,  2001, 345(24), 1734-1739.
 [http://dx.doi.org/10.1056/NEJMoa011127] [PMID:  11742047]

Cite As

Current Neuropharmacology

Pharmacological Treatment of Alcohol use Disorder in Patients with Psychotic Disorders: A Systematic Review

Abstract